DelveInsight’s, “Waldenstrom’s Macroglobulinaemia Pipeline Insight, 2023,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Waldenstrom’s Macroglobulinaemia pipeline landscape. It covers the Waldenstrom’s Macroglobulinaemia pipeline drug profiles, including Waldenstrom’s Macroglobulinaemia clinical trials and nonclinical stage products. It also covers the Waldenstrom’s Macroglobulinaemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Waldenstrom’s Macroglobulinaemia pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Waldenstrom’s Macroglobulinaemia clinical trials studies, Waldenstrom’s Macroglobulinaemia NDA approvals (if any), and product development activities comprising the technology, Waldenstrom’s Macroglobulinaemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Waldenstrom’s Macroglobulinaemia Pipeline Report

 

• DelveInsight’s Waldenstrom’s Macroglobulinaemia pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Waldenstrom’s Macroglobulinaemia treatment.

 

• The leading Waldenstrom’s Macroglobulinaemia Companies includes Amgen, Abbvie, Roche, Bristol-Myers Squibb, Mavorixafor, TransThera Sciences, and others.

 

• Promising Waldenstrom’s Macroglobulinaemia Pipeline Therapies includes Ibrutinib, Rituximab. Ofatumumab, Mavorixafor, Perifosine, BGB-3111, Acalabrutinib (ACP-196), Zanubrutinib, and others.

 

• The Waldenstrom’s Macroglobulinaemia companies and academics are working to assess challenges and seek opportunities that could influence Waldenstrom’s Macroglobulinaemia R&D. The Waldenstrom’s Macroglobulinaemia pipeline therapies under development are focused on novel approaches to treat/improve Waldenstrom’s Macroglobulinaemia.

 

To explore more information on the latest breakthroughs in the Waldenstrom’s Macroglobulinaemia Pipeline treatment landscape of the report, click here @ Waldenstrom’s Macroglobulinaemia Pipeline Outlook

 

Waldenstrom’s Macroglobulinaemia Overview

Waldenstrom’s Macroglobulinaemia is a rare type of cancer that begins in the white blood cells. In this the bone marrow produces too many white blood cells that crowd out the normal healthy blood cells. Waldenstrom macroglobulinaemia is considered a type of non-Hodgkin’s lymphoma. It’s is also sometimes called lymphoplasmacytic lymphoma. Waldenstrom macroglobulinaemia is slow growing and may not cause signs and symptoms for many years. When they occur the symptoms may include: easy bruising, fatigue, weight loss, fever, numbness in hands and feet’s, change in vision and shortness of breath. What causes Waldenstrom’s Macroglobulinaemia is still not clear. The disease generally begins with one abnormal white blood cell that develops errors (mutations) in its genetic code. The treatment options may include: chemotherapy, Plasma exchange, Targeted Therapy, Biological therapy and Bone marrow transplant.

 

Latest Developmental Activities in the Waldenstrom’s Macroglobulinaemia Treatment Landscape

 

• Obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody (mAb), has been described as being more effective than rituximab in low-grade lymphoid malignancies, including in unfit treatment-naive patients with chronic lymphocytic leukemia and in follicular lymphoma, resulting in longer PFS than with rituximab-based therapy.Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Waldenstrom Macroglobulinemia.

 

• ABT-199 ( vnetoclax), which is a Bcl-2 inhibitor. Bcl-2 is an apoptosis regulator expressed in high levels in leukemia cells, and it is responsible for the prolonged survival of these cells. Venetoclax will block and modulate the activity of Bcl-2. The clinical trials for ABT199 are being evaluated in phase II stage of development for the treatment of Waldenstrom’s Macroglobulinaemia in collaboration with Dana-Farber Cancer Institute. 

 

For further information, refer to the detailed Waldenstrom’s Macroglobulinaemia Unmet Needs, Waldenstrom’s Macroglobulinaemia Market Drivers, and Waldenstrom’s Macroglobulinaemia Market Barriers, click here for Waldenstrom’s Macroglobulinaemia Ongoing Clinical Trial Analysis

 

Waldenstrom’s Macroglobulinaemia Emerging Drugs Profile

 

• Obinutuzumab : Roche

 

• ABT199: Abbvie

 

Waldenstrom’s Macroglobulinaemia Pipeline Therapeutic Assessment

There are approx. 25+ key companies which are developing the therapies for Waldenstrom’s Macroglobulinaemia. The companies which have their Waldenstrom’s Macroglobulinaemia drug candidates in the most advanced stage, i.e. Phase II include, Roche.

 

Request a sample and discover the recent advances in Waldenstrom’s Macroglobulinaemia Ongoing Clinical Trial Analysis and Medications, click here @ Waldenstrom’s Macroglobulinaemia Treatment Landscape

 

Waldenstrom’s Macroglobulinaemia Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Waldenstrom’s Macroglobulinaemia Route of Administration

• Oral
• Subcutaneous
• Intravenous
• Intramuscular

 

Get to know more information about Waldenstrom’s Macroglobulinaemia therapeutics Assessment of the report @ Waldenstrom’s Macroglobulinaemia Product Type, Route of Administration, and Molecule Type

 

Scope of the Waldenstrom’s Macroglobulinaemia Pipeline Insight Report

• Coverage- Global
• Waldenstrom’s Macroglobulinaemia Companies- Amgen, Abbvie, Roche, Bristol-Myers Squibb, Mavorixafor, TransThera Sciences, and others.
• Waldenstrom’s Macroglobulinaemia Pipeline Therapies- Ibrutinib, Rituximab. Ofatumumab, Mavorixafor, Perifosine, BGB-3111, Acalabrutinib (ACP-196), Zanubrutinib, and others.
• Waldenstrom’s Macroglobulinaemia Pipeline Segmentation: Product Type, Route of Administration and Molecule Type

 

Dive deep into rich insights for drugs for Waldenstrom’s Macroglobulinaemia Market Drivers and v Market Barriers, click here @ Waldenstrom’s Macroglobulinaemia Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Waldenstrom’s macroglobulinaemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Waldenstrom’s macroglobulinaemia – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Waldenstrom’s macroglobulinaemia Collaboration Deals
9. Late Stage Products (Phase III)
10. Drug Name: Company name
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. ABT199: Abbvie
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. LP168: Newave Pharmaceutical Inc
17. Drug profiles in the detailed report…..
18. Preclinical Stage Products
19. Drug Name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Waldenstrom’s macroglobulinaemia Key Companies
23. Waldenstrom’s macroglobulinaemia Key Products
24. Waldenstrom’s macroglobulinaemia- Unmet Needs
25. Waldenstrom’s macroglobulinaemia- Market Drivers and Barriers
26. Waldenstrom’s macroglobulinaemia- Future Perspectives and Conclusion
27. Waldenstrom’s macroglobulinaemia Analyst Views
28. Waldenstrom’s macroglobulinaemia Key Companies
29. Appendix

 

Got Queries? Find out the related information on Waldenstrom’s Macroglobulinaemia Mergers and acquisitions, Waldenstrom’s Macroglobulinaemia Licensing Activities @ Waldenstrom’s Macroglobulinaemia Emerging Drugs, and Recent Trends

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services